Triton Wealth Management PLLC Purchases 199 Shares of Johnson & Johnson (NYSE:JNJ)

Triton Wealth Management PLLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,578 shares of the company’s stock after purchasing an additional 199 shares during the quarter. Johnson & Johnson accounts for about 0.4% of Triton Wealth Management PLLC’s investment portfolio, making the stock its 29th biggest holding. Triton Wealth Management PLLC’s holdings in Johnson & Johnson were worth $741,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Morningstar Investment Services LLC grew its position in Johnson & Johnson by 84.8% in the 4th quarter. Morningstar Investment Services LLC now owns 14,169 shares of the company’s stock worth $2,219,000 after purchasing an additional 6,503 shares during the period. Wescott Financial Advisory Group LLC boosted its position in Johnson & Johnson by 3.7% in the fourth quarter. Wescott Financial Advisory Group LLC now owns 9,323 shares of the company’s stock worth $1,461,000 after purchasing an additional 332 shares during the last quarter. Wealth Quarterback LLC grew its stake in shares of Johnson & Johnson by 107.7% during the 4th quarter. Wealth Quarterback LLC now owns 21,746 shares of the company’s stock valued at $3,408,000 after purchasing an additional 11,274 shares during the period. Waterloo Capital L.P. increased its position in shares of Johnson & Johnson by 169.3% during the 4th quarter. Waterloo Capital L.P. now owns 6,806 shares of the company’s stock valued at $1,067,000 after purchasing an additional 4,279 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $44,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, September 30th. Morgan Stanley raised their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, TD Cowen lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Stock Down 0.1 %

NYSE JNJ traded down $0.21 during trading on Friday, hitting $160.29. The company’s stock had a trading volume of 5,331,694 shares, compared to its average volume of 7,091,981. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a market cap of $385.77 billion, a PE ratio of 9.99, a P/E/G ratio of 2.69 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The business’s 50 day simple moving average is $162.60 and its 200-day simple moving average is $154.33.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.80 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.